Hofseth BioCare ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was NOK 85.28 million compared to NOK 61.43 million a year ago. Revenue was NOK 86.84 million compared to NOK 61.54 million a year ago. Net loss was NOK 99.12 million compared to NOK 89.27 million a year ago. Basic loss per share from continuing operations was NOK 0.27 compared to NOK 0.25 a year ago. Diluted loss per share from continuing operations was NOK 0.27 compared to NOK 0.25 a year ago.